Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 8/20 | 0.61 |
| ▸ | DDB1 | Q16531 | 7/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.36 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21997364 | 0.92 | CRBN (0.70) | CRBNDDB1IKZF2IKZF3IKZF1 | |
| Trifluoroacetic Acid SCHEMBL30112491 | 0.86 | CRBN (0.54) | CRBNDDB1IKZF2IKZF3 | |
| SCHEMBL30893289 | 0.85 | CRBN (0.59) | CRBNDDB1IKZF2IRAK4IKZF3 | |
| SCHEMBL22526727 | 0.83 | CRBN (0.64) | CRBNDDB1IKZF2IKZF3IKZF1 | |
| Trifluoroacetic Acid SCHEMBL30392280 | 0.83 | CRBN (0.54) | CRBNDDB1IKZF2IKZF3IKZF1 | |
| SCHEMBL30289264 | 0.83 | DDB1 (0.57) | CRBNDDB1MCHR1 | |
| SCHEMBL21996889 | 0.83 | CRBN (0.61) | CRBNDDB1IKZF2IKZF3IKZF1 | |
| Trifluoroacetic Acid SCHEMBL30304367 | 0.82 | CRBN (0.66) | CRBNDDB1IKZF2KCNH2 | |
| SCHEMBL24764683 | 0.82 | CRBN (0.70) | CRBNDDB1IKZF2IKZF3IKZF1 | |
| Trifluoroacetic Acid SCHEMBL30392701 | 0.82 | CRBN (0.53) | CRBNDDB1IKZF2IRAK4IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | C4 THERAPEUTICS, INC. | 2024-10-17 | — | — | US | disclosed |
| EP-4367113-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | Biogen MA Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117940414-A | Compounds for targeting IRAK4 protein degradation | 渤健马萨诸塞州股份有限公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023283610-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343733-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | IRAK4, IRAK2, IRAK1 | CRBN 193/4885DDB1 433/4885IKZF2 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.